---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-076851"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:25:36.069953+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio Q2 net loss $0.32/sh; cash $17.1M; Phase 3 AD trial advances with 38 patients randomized

## Summary
- Cash and cash equivalents $17.1M as of June 30, 2025, up from $10.6M at Dec 31, 2024.
- Net loss per share $0.32 (basic/diluted) for Q2 2025 vs $0.44 in Q2 2024.
- Phase 3 early AD trial: 38 patients randomized, nearly 200 in screening, 76 U.S. sites (46 enrolling).
- R&D expenses $5.2M, G&A $1.1M, both down YoY.
- Transferred all patent families to crystal buntanetap, achieving comprehensive global IP coverage.

## SEC filing metadata
- accession: 0001104659-25-076851
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465925076851/0001104659-25-076851-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465925076851/tm2523281d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-076851
- JSON: https://secwatch.observer/filing/0001104659-25-076851.json
- Plain text: https://secwatch.observer/filing/0001104659-25-076851.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.